DRUG TREATMENT WITH OZEMPIC FOR TYPE II DIABETES MELLITUS

Abstract

The objective of this study was to analyze the effectiveness of Ozempic (semaglutide) in the treatment of type 2 diabetes mellitus, evaluating its mechanism of action, clinical efficacy, and differences compared to other hypoglycemic therapies. To this end, an integrative, descriptive-exploratory literature review was conducted based on articles published between 2015 and 2025, available in full text and in Portuguese, obtained from the Virtual Health Library. After applying the eligibility criteria, 11 studies were selected for critical analysis. The results showed that semaglutide is highly effective in reducing glycated hemoglobin, glycemic control, and promoting weight loss, in addition to contributing to a reduced risk of cardiovascular events. Its advantages include weekly administration, greater treatment adherence, and a lower risk of hypoglycemia compared to other drugs. However, the drug has limitations, such as high cost, potential gastrointestinal adverse effects, and the need for strict monitoring. In conclusion, Ozempic represents a significant advance in the management of Type 2 Diabetes Mellitus, establishing itself as an effective and safe therapeutic option. However, caution is recommended when prescribing it, and longitudinal studies are recommended to further assess its cost-benefit and long-term impact.